Thomas B (@PJC3251) profile picture
Joined December 2023
Photo by Thomas B (@PJC3251)Photo by Thomas B (@PJC3251)Photo by Thomas B (@PJC3251)Photo by Thomas B (@PJC3251)Photo by Thomas B (@PJC3251)Photo by Thomas B (@PJC3251)Photo by Thomas B (@PJC3251)Photo by Thomas B (@PJC3251)Photo by Thomas B (@PJC3251)Photo by Thomas B (@PJC3251)
$NWBO For anyone who doubts that paid disinformation campaigns exist to suppress retail sentiment on certain stocks, look no further than @GREEK__G0D and @Tiggersdad2. For a while, I thought maybe they were just bored older guys desperate for engagement or wanting to feel relevance in a sad lonely life. But after today, I’m convinced—these guys are likely paid to undermine stocks like $NWBO and derail any constructive dialogue about its potential. Let’s talk about “Greek God.” He’s claimed multiple times that his sister has glioblastoma. On two occasions he claimed that her neuro-oncologist “smirked” at the mention of DCVax and made a statement that the trial was “flawed” Here’s the problem: the glioblastoma specialist at Capital Health is Dr. Michael Salacz—a listed contributor to the JAMA-published Phase III trial results for DCVax-L. Why would a lead investigator “smirk” at a treatment he publicly helped validate? That’s where the lie slipped. When I called out Greek God on this lie, he backtracked, saying it was a different doctor—but never clarified, then shut the conversation down entirely. That’s not a misunderstanding. That’s deliberate misdirection. Now zoom out. These guys claim to have no financial interest in $NWBO, yet they spend every single day trashing it. A simple scan of their post history and you’ll see that all they do is bash companies they deem “shitcos.” Why? If your sister had GBM, would you dedicate your time to tearing down a company working on the very treatment that could help her? More likely: they’re paid actors, part of a broader campaign to erode trust in vulnerable companies like $NWBO. Whether funded by short interests or PR hit firms, their goal is clear—create confusion, spread doubt, and suppress sentiment. Retail needs to be aware of how subtle and persistent these tactics are. This isn’t organic skepticism—it’s manufactured noise. And it’s time we start calling it out.
9
14
2
145
9,497
$NWBO — IMO, the positive news and momentum over the past 90 days rival any period outside the Phase III trial milestone. Risks remain, and continued dilution is painful, but I believe the case for DCVax-L’s potential and a path to regulatory approval is getting harder to dismiss. Hoping the remaining hurdles with @MHRAgovuk are resolved soon so more patients can access the treatment and the company can move toward financial stability and ultimately resolve its going-concern uncertainty.
1
11
64
1,271
$NWBO Momentum.
1
2
43
689
Please help me…I never ask for help for others unless I ALSO help first…this young woman needs money for life saving treatment for serious cancer ONLY available in UK but created here in USA.. if my 1.2m followers help, we save her life - please give even just $20 THANK YOU gofund.me/829384254
46
159
22
390
48,895
$nwbo One of the challenges with an investment like NWBO is that most people naturally evaluate it the same way they would an established public company. Dev stage biotech is fundamentally different. You’re trying to assess the probability and potential value of a future outcome while the company is operating with limited capital, limited personnel, regulatory uncertainty, and very little traditional revenue. That makes the risk/reward analysis complicated, and it also means management decisions that look questionable in isolation may make considerably more sense when viewed through the lens of limited resources. My thesis has been that NWBO has deliberately chosen what it believes is the most capital efficient and achievable path to bringing DCVax-L to market: establish approval and commercialization in the UK first, where it has already invested heavily in the regulatory and manufacturing infrastructure, and then build outward from that foundation. A dev stage company simply doesn’t have the resources of a Merck or Bristol Myers Squibb. It can’t necessarily pursue every regulatory jurisdiction, manufacturing expansion, clinical program, combination trial, and commercialization initiative simultaneously. Management has to prioritize. That inevitably means some things move more slowly than investors would like and that scarce capital gets directed toward the steps management believes have the highest probability of moving the entire platform forward. That’s an important part of the investment thesis. The question isn’t whether NWBO has executed perfectly, it clearly hasn’t. The question is whether the value potentially created by successfully getting DCVax-L through its first major regulatory approval materially outweighs the risks, dilution, delays, and financing challenges required to reach that point. If the UK strategy (and now potentially Middle East) succeeds, the company is no longer trying to sell investors and potential partners purely on a dev stage hypothesis. It potentially has an approved product, a validated manufacturing process, real-world commercial experience, and a regulatory foundation from which it can pursue additional markets and indications. That could fundamentally change both the company’s risk profile and its negotiating leverage. That’s why I think it can be difficult to understand NWBO by looking at individual decisions without considering the larger strategy. My interpretation is that management has been trying to cross the most important bridge first with the resources available to them: get DCVax-L approved and commercially established somewhere, beginning with the UK, and then use that foundation to pursue the much larger opportunity. Whether they ultimately succeed is obviously the risk we are taking as investors. But that’s also why the potential reward exists. If success were obvious, fully funded, and universally understood, the opportunity would presumably already be reflected in the valuation.
4
2
81
2,577
$NWBO 6 years of accumulation and today I’m taking a crack at getting to 2 million shares if order fills. This isn’t a sure thing but is a high conviction play for me and others that truly believe DCVax is the game changer vaccine and platform that will save lives for people battling glioblastoma. #fuckcancer
4
4
99
1,836
$NWBO Of course I try to buy the dip and then it starts rising before my order can execute! Would love to have some shares at a sub $0.15....
5
24
1,202
$NWBO Things that make you go hmmm This order did eventually fill but strange that the buy and ask fell below my order for a few minutes before executing Ready for @MHRAgovuk to get this over the finish line!
4
4
60
2,106
Hey @MHRAgovuk Tomorrow is my birthday, how about we just go ahead and grant MAA approval to $NWBO DCvaxL. If you haven’t rejected at this point, I’m sure we can figure out how to address open items post approval. Excellent safety profile + statistically meaningful improvement = No Brainer
1
4
66
1,412
$nwbo Still going thru 10-k but found the paragraph on third party secondary manufacturing site interesting. Seems to indicate management feels they may need additional production capacity in the near term which feels bullish af.
3
6
83
1,843
$NWBO borrow rate jumped from 7.7% to 10%. Available shares have dwindled as well. Borrow rates haven’t been this high since last October. Shorts might be thinking approval is coming and looking to close out or just taking advantage to close out at this level. Either way, the popcorn is ready. iborrowdesk.com/report/NWBO
3
7
1
82
3,283
$NWBO, gotta wonder “In October 2025, pharmaceutical companies were invited to register as early adopters. A total of 27 companies signed up, and the first treatments are currently going through the aligned pathway, with the first guidance expected in June 2026” gov.uk/government/news/patie…
3
32
1,409
$NWBO- added 40,000 shares at .233. I like that 350 million MC as a support level until MHRA decision. DYOR. Fingers and toes crossed for MAA soon....
9
1
70
2,211
@grok does the UK Rare Cancers Bill effectively shift cancer regulation from judging therapies by single indications to judging them by method or platform, especially for orphan and rare cancers?
1
1
9
338
$NWBO shorts You assumed this would be an easy trade, a quiet biotech that would fade to oblivion. Obviously, a company with limited capital partners and a long Phase 3 runway looked helpless from the outside. Understandable, on paper, patience is expensive and conviction is rare. And yet, you mistook restraint for weakness and science for silence. Remember, extended trials don’t erase data, they refine it. Every month you waited for collapse, progress kept compounding. Funding didn’t vanish and the thesis didn’t break. Unfortunately for you, reality doesn’t always trade on models. Confidence cuts both ways. Keep pressing if you like, liquidity works both ways when the float tightens. Eventually, the story stops being about survival and starts being about outcomes. Draw your own conclusion,this isn’t going to be the easy target you priced in.
2
3
71
2,307
I guess I’m officially at the age where multiple group texts are blowing up before 7 a.m. on Christmas morning and we’re all apparently awake and ready to respond. Merry Christmas, friends. Here’s hoping Santa delivers @MHRAgovuk approval for $NWBO. 🎄🎅
3
4
70
1,864
$NWBO I had a good call with George Zavoico this afternoon regarding the increase in authorized shares and the status of the MHRA review. He was surprisingly candid on both topics. George explained that throughout the summer and into early fall, the company was in active communication with the MHRA and responded to several RFIs. His exact words were that the company had provided “a ton of additional information.” At this point, the process is entirely in the MHRA’s hands as they complete their review and, hopefully, move toward a decision. While they remain optimistic that a positive outcome is imminent, he acknowledged that additional inquiries are still possible. In the meantime, he reiterated what we already know that the company is preparing for approval by ramping up commercialization efforts and focusing on additional trials. Overall, his tone was notably positive, with the one exception being management’s shared frustration over how long the review has taken, an issue that ties directly into the request for increased authorized shares. George made it clear that the company needs to ensure it has a sufficient runway to fund operations, especially given the uncertainty around when revenue will begin. He stated what we have seen consistently over the past few years: they will only dilute when absolutely necessary to keep the company moving forward. While I’m not pleased about the prospect of further dilution, I now understand the motive and necessity. My investment in this company is driven more by the desire to see this treatment reach patients than by concerns about short-term profitability, though I recognize not everyone shares that perspective. I will be voting yes across the board.
15
16
4
111
6,422